Osteoporosis Risk Assessment Instrument (ORAI)

Why use it

Osteoporosis affects approximately 10% of women over 50 and is responsible for over 200 million fractures worldwide annually. DEXA scanning is the gold standard for BMD measurement, but universal screening is resource-intensive. The ORAI provides a simple, three-variable screen that can be administered in under 1 minute in primary care, identifying which women should be prioritized for DEXA. It avoids unnecessary scans while maintaining high sensitivity for true low BMD.

About

The Osteoporosis Risk Assessment Instrument (ORAI) is a validated clinical screening tool developed by Cadarette and colleagues and published in JAMA in 2000. It was designed to identify women at increased risk of low bone mineral density (BMD) — specifically, a T-score ≤ −1.0 at the hip or lumbar spine — who should be referred for dual-energy X-ray absorptiometry (DEXA) scanning. The ORAI uses three variables: age, weight, and current estrogen use. Each variable is assigned weighted points based on its independent contribution to fracture risk in the derivation study. Scores range from 0 to 31. A score ≥9 identifies women with a sensitivity of 93.3% and specificity of 46.4% for low BMD. The ORAI was developed and validated in a Canadian cohort of 1,376 women aged 45 years or older. It is simpler than the FRAX algorithm (which requires fracture history and multiple comorbidities) and performs comparably to or better than several competing screening tools (SCORE, ABONE, age alone) for identifying candidates for DEXA in primary care settings.

When to use

• Screening women aged 45 years or older in primary care to determine need for DEXA referral
• Peri- and postmenopausal women with no prior DEXA scan or prior normal DEXA >5 years ago
• Women with risk factors for osteoporosis (low body weight, estrogen deficiency, family history) to determine urgency of DEXA
• NOT validated in men — use FRAX or MORES for male osteoporosis screening
• NOT a substitute for DEXA in women with known osteoporosis, prior fragility fractures, or on osteoporosis pharmacotherapy

Formula

Pearls & pitfalls

• The three variables — age, weight, and estrogen use — are easily obtained and require no laboratory tests, making the ORAI practical for screening in any clinical setting.
• Weight is the single most powerful predictor in the ORAI — low body weight (<60 kg) adds the maximum score. Low weight reduces bone loading and is a major independent risk factor for osteoporosis.
• Current estrogen use reduces osteoporosis risk substantially and is rewarded with a 0-point score for that domain; non-users receive 2 points.
• A threshold of ≥9 provides sensitivity of 93.3% for detecting T-score ≤ −1.0 — this is intentionally sensitive to ensure low-BMD patients are not missed. The modest specificity (46.4%) means many positive screens will have normal or osteopenic (not osteoporotic) BMD.
• The ORAI was validated for T-score ≤ −1.0 (osteopenia or worse), not just osteoporosis (T-score ≤ −2.5). This ensures earlier detection before full osteoporosis is established.
• In settings without DEXA access, FRAX (WHO Fracture Risk Assessment Tool) can estimate 10-year fracture probability without BMD as an alternative management guide.
• The ORAI does not include glucocorticoid use, family history, or prior fracture — patients with these risk factors should be considered for DEXA regardless of ORAI score.
• Do not use the ORAI to follow up patients already on osteoporosis treatment — use DEXA at 2-year intervals for monitoring.

Next steps

Score ≥9 (ORAI Positive): Refer for DEXA scanning of lumbar spine and hip. If DEXA confirms osteoporosis (T-score ≤ −2.5): initiate pharmacological treatment (bisphosphonate first-line — alendronate or risedronate; denosumab, romosozumab, or zoledronic acid for high-risk or unable to take oral bisphosphonates). Calcium 1000–1200 mg/day and vitamin D 800–1000 IU/day supplementation. Fall prevention assessment. Score <9 (ORAI Negative): Routine monitoring. Reassess risk factors annually. Consider DEXA if new risk factors emerge (new fracture, corticosteroid use, weight loss). Standard bone health counseling (weight-bearing exercise, calcium, vitamin D, smoking cessation, alcohol moderation).

Evidence

Cadarette SM et al. Development and validation of the Osteoporosis Risk Assessment Instrument to facilitate selection of women for bone densitometry. CMAJ. 2000;162(9):1289-1294. PMID:10813010. Derived in 1,376 women ≥45 years; ORAI ≥9: sensitivity 93.3%, specificity 46.4% for T-score ≤−1.0; AUC 0.79. Compared favorably to SCORE, ABONE, age alone, and body weight alone in comparative studies. Endorsed by Osteoporosis Canada and multiple national guidelines as a valid pre-screening tool.

References

1. Cadarette SM et al. Development and validation of the Osteoporosis Risk Assessment Instrument to facilitate selection of women for bone densitometry. CMAJ. 2000;162(9):1289-1294. — link
2. Cadarette SM et al. Osteoporosis Risk Assessment Instrument. Osteoporos Int. 2004;15(5):361-366. — link
3. Kanis JA et al. FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int. 2008;19(4):385-397. — link